Table 2.
Characteristics of the included studies (n = 11).
| Study, Year | Design and Centers |
Geographical Area | No. of Patients |
No. of Patients Reflecting Our EC and IC | Type of Malignancy | Type of BD |
Type of Biliary Stent | Treatment of MGOO | First Procedure Performed |
Time between the Two Procedures | Follow-Up | AEs, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Iwamuro, 2010 [30] |
Retrospective/ Single-center |
Eastern | 7 | 2 | Pancreatic (n = 2) | EUS-BD | Plastic stent | Duodenal stenting | MGOO | Simultaneous | 46.4 w and 9.9 w | 1 (50) |
|
Maluf-Filho, 2012 [31] |
Retrospective/ Single-center |
Western | 5 | 5 | Pancreatic (n = 3) Cervix squamous cell cancer (n = 1) Colonic adenocarcinoma (n = 1) |
EUS-BD | PC-SEMS (n = 4) and U-SEMS (n = 1) | Duodenal stenting | Biliary | Simultaneous | 3 m + 17 d + 2 m + 4 d + 15 d | 3 (60) |
|
Rebello, 2012 [32] |
Prospective/ Single-center |
Western | 7 | 7 | Pancreatic (n = 7) | EUS-BD | PC-SEMS | Duodenal stenting | Biliary | Simultaneous | 140 days | 0 (0) |
|
Tonozuka, 2013 [33] |
Retrospective/ Single-center |
Eastern | 11 | 4 | Pancreatic (n = 4) | EUS-BD | C-SEMS | Duodenal stenting | MGOO | Simultaneous | Survival time: 37 d, 74 d, 23 d, 69 d | 2 (50) |
|
Ogura, 2016 [34] |
Retrospective/ Single-center |
Eastern | 39 | 39 | EUS-CDS group: 11 pancreaticobiliary cancers and 2 others; EUS-HGS group: 21 pancreaticobiliary cancers and 5 others |
EUS-CDS and EUS-HGS | FC metal stent | Duodenal stenting | MGOO | Within 7 days | OS: EUS-CDS median 98 days, EUS-HGS median 133 days | 8 (20.5) |
|
Sato, 2016 [35] |
Retrospective/ Single-center |
Eastern | 43 | 17 | NA | EUS-CDS (n = 16) EUS-HGS (n = 1) |
C-SEMS | Duodenal stenting | NA | Simultaneous | Death or 90 days | NA |
|
Hamada, 2018 [36] |
Retrospective/ Multicenter |
Western | 110 | 20 | Pancreatic (n = 72) Biliary (n = 9) Gastric (n = 9) Ampullary (n = 9) Gallbladder (n = 9) Others (n = 9) |
EUS-CDS (n = 10) EUS-HGS (n = 10) |
SEMS, Plastic |
Duodenal stenting | NA | Simultaneous or within 7 days | 450 days, median | 7 (35%) |
|
Debourdeau, 2021 [37] |
Retrospective/ Single-center |
Western | 31 | 7 | NA | EUS-HGS (n = 11) EUS-CDS (n = 1) |
PC-SEMS | Duodenal stenting | Biliary Or MGOO |
Simultaneous or within 7 days | NA | NA |
|
Mangiavillano, 2021 [40] |
Retrospective/ Multicenter |
Western | 23 | 23 | Pancreatic adenocarcinoma (n = 13) Advanced ampulloma (n = 2) Metastasis (n = 2) Biliary tumor (n = 2) Pancreatic NET (n = 1) Duodenal adenocarcinoma (n = 1) Gallbladder neoplasia (n = 1) Recurrence of a previous distal esophageal adenocarcinoma (n = 1) |
EUS-CDS (n = 9) EUS-GDS (n = 14) |
LAMS | Duodenal stenting | Duodenal stenting | Simultaneous or within 7 days | 241 days, median | 0 (0) |
|
Canakis, 2022 [39] |
Retrospective/ Mulitcenter |
Western | 23 | 21 | Pancreatic cancer (n = 16) Breast metastasis (n = 2) Cholangiocarcinoma (n = 2) Colon (n = 1) |
EUS-HGS | FC-SEMS | EUS-GEA | BiliaryOrMGOO | Simultaneous | 78 days, median | 3 (14.3) |
|
Sasaki, 2022 [38] |
Retrospective/ Single-center |
Eastern | 38 | 5 | Pancreatic (n = 28) | EUS-CDS (n = 1) EUS-HGS (n = 4) |
PC-SEMS | Duodenal stenting | NA | Simultaneous | NA | NA |
EC = exclusion criteria; IC = inclusion criteria; BD = biliary drainage; EUS-BD = endoscopic ultrasound biliary drainage; PC-SEMS = partially covered self-expandable metal stent; MGOO = malignant gastric outlet obstruction; AEs = adverse events; C-SEMS = covered self-expandable metal stent; FCSEMS = fully covered self-expandable metal stent; NA = Not Available; LAMS = lumen apposing metal stent; EUS-CDS = endoscopic ultrasound choledocoduodenostomy; EUS-GDS = endoscopic ultrasound gallbladderduodenostomy; EUS-HGS = endoscopic ultrasound hepaticogastrostomy; OS = overall survival.